Re: "A prospective study of the effectiveness of the New Zealand meningococcal B vaccine"

American Journal of Epidemiology

Volumn 167, Issue 9, 2008, Pages 1140-1141

  Lennon, Diana ^a   Stewart, Joanna ^a   Crengle, Sue ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; MENINGOCOCCUS VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; CONFIDENCE INTERVAL; DRUG EFFICACY; ETHNICITY; GROUPS BY AGE; HUMAN; INFECTION RISK; LETTER; MENINGOCOCCOSIS; NEW ZEALAND; RISK ASSESSMENT; RISK FACTOR; UNITED KINGDOM; VACCINATION;

CHILD, PRESCHOOL; CONFOUNDING FACTORS (EPIDEMIOLOGY); CROWDING; DISEASE PROGRESSION; HUMANS; INFANT; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEW ZEALAND; OCEANIC ANCESTRY GROUP; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 42549159319     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwn051     Document Type: Letter

References (9)

1. Kelly C, Arnold R, Galloway Y, et al. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol 2007;166:817-23.
2. Dyet K, Devoy A, McDowell R, et al. New Zealand's epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery. Vaccine 2005;23:2228-30.
3. Baker M, McNicholas A, Garrett N, et al. Household crowding a major risk factor for epidemic meningococcal disease in Auckland children. Pediatr Infect Dis J 2000;19:983-90.
4. Oster P, Lennon D, O'Hallahan J, et al. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005;23:2191-6.
5. Oster P, O'Hallahan J, Aaberge I, et al. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. Vaccine 2007;25:3075-9.
6. Boslego J, Garcia J, Cruz C, et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 1995;13:821-9.
7. Milagres LG, Ramos SR, Sacchi CT, et al. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun 1994;62:4419-24.
8. Holst J, Feiring B, Fuglesang JE, et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 2003;21:734-7.
9. MacLennan JM, Shackley F, Heath PT, et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA 2000;283:2795-801.